X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
aged (6) 6
female (6) 6
male (6) 6
middle aged (6) 6
neurosciences (5) 5
parkinson's disease (5) 5
adult (4) 4
aids/hiv (4) 4
cabergoline (4) 4
pharmacokinetics (4) 4
clarithromycin (3) 3
clinical neurology (3) 3
drug-drug interaction (3) 3
neurology (3) 3
parkinson disease - drug therapy (3) 3
pharmacology & pharmacy (3) 3
animals (2) 2
antibodies (2) 2
antiparkinson agents - pharmacokinetics (2) 2
area under curve (2) 2
drug interactions (2) 2
drug therapy (2) 2
electromyography (2) 2
htlv-i-associated myelopathy (2) 2
individuality (2) 2
levodopa - pharmacokinetics (2) 2
medicine & public health (2) 2
molecular sequence data (2) 2
neuroradiology (2) 2
paraparesis, tropical spastic - physiopathology (2) 2
parkinson disease - metabolism (2) 2
parkinson’s disease (2) 2
renal insufficiency - metabolism (2) 2
virus type-i (2) 2
5-ht2b receptors (1) 1
aged, 80 and over (1) 1
agonist (1) 1
agonists (1) 1
alkaline-phosphatase (1) 1
als (1) 1
amino acid sequence (1) 1
amino acid substitution (1) 1
amino acids (1) 1
amyotrophic lateral sclerosis (1) 1
amyotrophic lateral sclerosis - genetics (1) 1
amyotrophic lateral sclerosis - pathology (1) 1
anti-bacterial agents - pharmacology (1) 1
antiparkinson agents - therapeutic use (1) 1
asian continental ancestry group (1) 1
asian continental ancestry group - genetics (1) 1
atp binding cassette transporter, subfamily b, member 1 - antagonists & inhibitors (1) 1
atp binding cassette transporter, subfamily b, member 1 - metabolism (1) 1
base sequence (1) 1
bone (1) 1
bone density conservation agents - pharmacokinetics (1) 1
brain - pathology (1) 1
brain - virology (1) 1
canada (1) 1
cardiac-valve regurgitation (1) 1
case-control studies (1) 1
cd4-positive t-lymphocytes - metabolism (1) 1
cd4-positive t-lymphocytes - virology (1) 1
cell leukemia-virus (1) 1
cell line (1) 1
cells, cultured (1) 1
central motor (1) 1
central sensory conduction time (1) 1
central sensory condution time (1) 1
central-nervous-system (1) 1
cerebrospinal-fluid (1) 1
clarithromycin - pharmacology (1) 1
clinical pharmacokinetics (1) 1
cognition & reasoning (1) 1
complications and side effects (1) 1
conduction (1) 1
controls (1) 1
creatinine clearance (1) 1
culture techniques (1) 1
cyp3a4 (1) 1
de-novo mutations (1) 1
dementia (1) 1
development and progression (1) 1
disability (1) 1
disability score (1) 1
disease (1) 1
distribution (1) 1
dna mutational analysis (1) 1
domain (1) 1
domperidone - pharmacokinetics (1) 1
dopamine (1) 1
dopamine agonist (1) 1
dopamine agonists - blood (1) 1
dopamine agonists - pharmacokinetics (1) 1
dopamine agonists - therapeutic use (1) 1
dopamine antagonists - pharmacokinetics (1) 1
dose (1) 1
drug interaction (1) 1
effect (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American Journal of Human Genetics, ISSN 0002-9297, 11/2013, Volume 93, Issue 5, pp. 900 - 905
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, 2012, Volume 119, Issue 4, pp. 324 - 329
Journal Article
Journal of Neurology, ISSN 0340-5354, 8/2006, Volume 253, Issue S3, pp. iii53 - iii59
The efforts to treat Parkinson’s disease have resulted in the development of numerous medicines, including L-dopa, 3.4-dihydroxyphenylalanine (DOPA)... 
Neurology | Neurosciences | vigilance | Medicine & Public Health | individual variations | pharmacokinetics | CYP3A4 | Neuroradiology | Parkinson’s disease
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, 2006, Volume 100, Issue 1, pp. 59 - 64
Cabergoline is used in the treatment of Parkinson's disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often... 
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, 2006, Volume 100, Issue 1, pp. 59 - 64
Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often... 
cabergoline | clarithromycin | drug-drug interaction | Parkinson’s disease
Journal Article
Rinsho shinkeigaku = Clinical neurology, ISSN 0009-918X, 11/2005, Volume 45, Issue 11, pp. 895 - 898
In the treatment of Parkinson's disease, levodopa, DCI, MAO-B inhibitor, COMT inhibitors, dopamine receptor agonists, amantadine, anticholinergics have been... 
Antiparkinson Agents - pharmacokinetics | Drug Interactions | Area Under Curve | Domperidone - pharmacokinetics | Dopamine Antagonists - pharmacokinetics | Humans | Individuality | Levodopa - pharmacokinetics | Parkinson Disease - drug therapy | Parkinson Disease - metabolism | Index Medicus
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, Volume 100, Issue 1, pp. 59 - 64
Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often... 
Journal Article
Journal of Neurovirology, ISSN 1355-0284, 06/1999, Volume 5, Issue 3, pp. 241 - 248
We investigated the role of viral transcripts of human T-lymphotropic virus type I (HTLV-I) in the cerebrospinal fluid (CSF) cells and peripheral blood... 
fluorescein
Journal Article
Journal of Pharmacological Sciences, ISSN 1347-8613, Volume 119, Issue 4, pp. 324 - 329
The effect of renal impairment on the pharmacokinetics of a single oral dose of memantine (10 mg) was determined in Japanese subjects. Subjects were assigned... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.